These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29250199)

  • 1. ASCO update on lymphoma.
    Fridrik MA
    Memo; 2017; 10(4):218-219. PubMed ID: 29250199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.
    Schöder H; Noy A; Gönen M; Weng L; Green D; Erdi YE; Larson SM; Yeung HW
    J Clin Oncol; 2005 Jul; 23(21):4643-51. PubMed ID: 15837966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aggressive phase multiple myeloma: a terminal anaplastic transformation resembling high-grade lymphoma.
    Allen SL; Coleman M
    Cancer Invest; 1990; 8(3-4):417-24. PubMed ID: 2207767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Divergence Analysis of Hepatitis Virus Infection between Aggressive and Indolent B Cell Non-Hodgkin's Lymphoma].
    Xiong WJ; Li H; Liu HM; Yi SH; Li ZJ; Lu R; Liu W; Zou DH; Qiu LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1754-1758. PubMed ID: 28024489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canine indolent and aggressive lymphoma: clinical spectrum with histologic correlation.
    Aresu L; Martini V; Rossi F; Vignoli M; Sampaolo M; Aricò A; Laganga P; Pierini A; Frayssinet P; Mantovani R; Marconato L
    Vet Comp Oncol; 2015 Dec; 13(4):348-62. PubMed ID: 23782432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease Progression in a Patient With Indolent T-Cell Lymphoproliferative Disease of the Gastrointestinal Tract.
    Perry AM; Bailey NG; Bonnett M; Jaffe ES; Chan WC
    Int J Surg Pathol; 2019 Feb; 27(1):102-107. PubMed ID: 29986618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymidine kinase levels correlate with prognosis in aggressive lymphoma and can discriminate patients with a clinical suspicion of indolent to aggressive transformation.
    Gatt ME; Goldschmidt N; Kalichman I; Friedman M; Arronson AC; Barak V
    Anticancer Res; 2015 May; 35(5):3019-26. PubMed ID: 25964590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Hodgkin lymphoma in elderly patients: experience at Taipei Veterans General Hospital.
    Bai LY; Yang MH; Chiou TJ; Liu JH; Yen CC; Wang WS; Hsiao LT; Chao TC; Chen PM
    Cancer; 2003 Sep; 98(6):1188-95. PubMed ID: 12973842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The broad and challenging landscape of extranodal lymphoproliferations.
    Dotlic S; Ponzoni M; King RL; Oschlies I; Ferry J; Calaminici M; Montes-Moreno S; Goodlad JR; Ott G; Traverse-Glehen A
    Virchows Arch; 2020 May; 476(5):633-646. PubMed ID: 31758317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma.
    Katodritou E; Dimopoulos MA; Zervas K; Terpos E
    Cancer Treat Rev; 2009 Dec; 35(8):738-43. PubMed ID: 19733008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine: role and evidence in lymphoma therapy, an overview.
    Derenzini E; Zinzani PL; Cheson BD
    Leuk Lymphoma; 2014 Jul; 55(7):1471-8. PubMed ID: 24180334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of hepatitis B virus infection in patients with aggressive B cell non-Hodgkin's lymphoma in China.
    Wang C; Xia B; Ning Q; Zhao H; Yang H; Zhao Z; Wang X; Wang Y; Yu Y; Zhang Y
    Ann Hematol; 2018 Mar; 97(3):453-457. PubMed ID: 29188315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment and outcomes of primary breast lymphoma.
    Caon J; Wai ES; Hart J; Alexander C; Truong PT; Sehn LH; Connors JM
    Clin Breast Cancer; 2012 Dec; 12(6):412-9. PubMed ID: 23018097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
    Amorim S; Stathis A; Gleeson M; Iyengar S; Magarotto V; Leleu X; Morschhauser F; Karlin L; Broussais F; Rezai K; Herait P; Kahatt C; Lokiec F; Salles G; Facon T; Palumbo A; Cunningham D; Zucca E; Thieblemont C
    Lancet Haematol; 2016 Apr; 3(4):e196-204. PubMed ID: 27063978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indolent T- and NK-cell lymphoproliferative disorders of the gastrointestinal tract: a review and update.
    Matnani R; Ganapathi KA; Lewis SK; Green PH; Alobeid B; Bhagat G
    Hematol Oncol; 2017 Mar; 35(1):3-16. PubMed ID: 27353398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas.
    Montes-Moreno S; King RL; Oschlies I; Ponzoni M; Goodlad JR; Dotlic S; Traverse-Glehen A; Ott G; Ferry JA; Calaminici M
    Virchows Arch; 2020 May; 476(5):667-681. PubMed ID: 31773249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASCO 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma: Guideline Summary.
    J Oncol Pract; 2007 Jul; 3(4):236. PubMed ID: 29452503
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral cyclophosphamide therapy for patients with residual or relapsed indolent-type lymphoma after initial treatment for aggressive lymphomas. A sub-group of patients with apparent transformed indolent lymphoma.
    Riccioni R; Galimberti S; Cervetti G; Fazzi R; Caracciolo F; Petrini M
    Leuk Lymphoma; 2002 Sep; 43(9):1803-6. PubMed ID: 12685835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow cytometric S-phase fraction as a complementary biological parameter for the cytological grading of non-Hodgkin's lymphoma.
    Pinto AE; Cabeçadas J; Nóbrega SD; Mendonça E
    Diagn Cytopathol; 2003 Oct; 29(4):194-9. PubMed ID: 14506670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin lymphoma.
    van de Loosdrecht AA; Huijgens PC; Ossenkoppele GJ
    Curr Opin Hematol; 2004 Nov; 11(6):419-25. PubMed ID: 15548997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.